These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

846 related items for PubMed ID: 23206211

  • 1. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ.
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [Abstract] [Full Text] [Related]

  • 2. Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder.
    Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson TM, Xie J, Erder MH, Dammerman RS, Robertson B, Wu EQ.
    Am J Manag Care; 2014 Sep; 20(9):711-21. PubMed ID: 25365746
    [Abstract] [Full Text] [Related]

  • 3. Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in quebec.
    Lachaine J, De G, Sikirica V, Van Stralen J, Hodgkins P, Yang H, Heroux J, Ben Amor L.
    Can J Psychiatry; 2014 Nov; 59(11):597-608. PubMed ID: 25565476
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy.
    Sohn M, Talbert J, Moga DC, Blumenschein K.
    Atten Defic Hyperact Disord; 2016 Sep; 8(3):149-58. PubMed ID: 27143026
    [Abstract] [Full Text] [Related]

  • 6. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Predictors of concomitant use of antipsychotics and stimulants and its impact on stimulant persistence in pediatric attention deficit hyperactivity disorder.
    Bali V, Kamble PS, Aparasu RR.
    J Manag Care Spec Pharm; 2015 Jun; 21(6):486-98. PubMed ID: 26011550
    [Abstract] [Full Text] [Related]

  • 9. Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy.
    Wade RL, Kindermann SL, Hou Q, Thase ME.
    J Manag Care Pharm; 2014 Jan; 20(1):76-85. PubMed ID: 24372461
    [Abstract] [Full Text] [Related]

  • 10. Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder.
    Sultan RS, Wang S, Crystal S, Olfson M.
    JAMA Netw Open; 2019 Jul 03; 2(7):e197850. PubMed ID: 31348506
    [Abstract] [Full Text] [Related]

  • 11. Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder.
    Olfson M, Marcus SC, Zhang HF, Wan GJ.
    J Manag Care Pharm; 2007 Sep 03; 13(7):570-7. PubMed ID: 17874863
    [Abstract] [Full Text] [Related]

  • 12. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P, Sikirica V, Chen YJ, Curtice TG, Makin C.
    Eur J Health Econ; 2017 Sep 03; 18(7):893-904. PubMed ID: 27817164
    [Abstract] [Full Text] [Related]

  • 13. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
    Molife C, Haynes VS, Nyhuis A, Faries DE, Gelwicks S, Kelsey DK, Alatorre CI.
    Curr Med Res Opin; 2018 Apr 03; 34(4):619-632. PubMed ID: 29298540
    [Abstract] [Full Text] [Related]

  • 14. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
    Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T.
    Clin Ther; 2013 Dec 03; 35(12):1867-75. PubMed ID: 24119767
    [Abstract] [Full Text] [Related]

  • 15. Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
    Setyawan J, Hodgkins P, Guérin A, Gauthier G, Cloutier M, Wu E, Erder MH.
    J Med Econ; 2013 Oct 03; 16(10):1203-15. PubMed ID: 23937642
    [Abstract] [Full Text] [Related]

  • 16. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE, Kratochvil CJ.
    Drugs; 2010 Oct 03; 70(1):15-40. PubMed ID: 20030423
    [Abstract] [Full Text] [Related]

  • 17. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A, Greene M, Hartry A, Burudpakdee C.
    J Med Econ; 2018 Sep 03; 21(9):888-901. PubMed ID: 29862860
    [Abstract] [Full Text] [Related]

  • 18. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M, Osman E.
    Turk Psikiyatri Derg; 2022 Sep 03; 33(2):146-148. PubMed ID: 35730516
    [Abstract] [Full Text] [Related]

  • 19. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.
    J Manag Care Spec Pharm; 2018 Jun 03; 24(6):525-533. PubMed ID: 29799328
    [Abstract] [Full Text] [Related]

  • 20. Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics.
    Rajagopalan K, Rashid N, Kumar S, Doshi D.
    J Med Econ; 2023 Jun 03; 26(1):34-42. PubMed ID: 36444507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.